Advance Search
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
DAI Yingxue, WANG Yao, DU Xunbo, . Characteristics of Omicron variant-induced SARS-CoV-2 reinfections in Chengdu, China[J]. Chinese Journal of Public Health, 2023, 39(4): 442-447. doi: 10.11847/zgggws1141316
Citation: DAI Yingxue, WANG Yao, DU Xunbo, . Characteristics of Omicron variant-induced SARS-CoV-2 reinfections in Chengdu, China[J]. Chinese Journal of Public Health, 2023, 39(4): 442-447. doi: 10.11847/zgggws1141316

Characteristics of Omicron variant-induced SARS-CoV-2 reinfections in Chengdu, China

doi: 10.11847/zgggws1141316
  • Received Date: 2023-01-16
    Available Online: 2023-02-03
  • Publish Date: 2023-04-10
  •   Objective  To explore the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections caused by Omicron variant for providing a reference to the containment of SARS-CoV-2 reinfection.   Methods  From China Information System for Disease Control and Prevention, we extracted 2 567 registered cases of 5 local coronavirus disease 2019 (COVID-19) epidemics in Chengdu city from February to September, 2022. Telephone follow-up surveys were conducted among the cases and their family members to collect the information on demographic characteristics, clinical symptoms, and viral nucleic acid or antigen tests in previous one month. The information on participants' COVID-19 vaccination were extracted from Immunization Program Information Management System of Sichuan Province. Data analyses were performed with SPSS 19.0.   Results  For the 2 263 eligible respondents (88.16% of all the participants), 44.68% were male and 55.32% were female; the ages of the respondents ranged from one month to 90 years, with the mean age of 34.88 ± 19.22 years; the majority (61.82%) of the respondents were mild cases and 31.64% were asymptomatic cases; 55.86% and 29.56% of the respondents reported having been vaccinated with 3 and 2 doses of COVID-19 vaccine. Based on genome sequencing on virus strains isolated from the cases of the 5 local epidemics, the most (98.89%) of the sufferers of the 5 epidemics were infected with Omicron subvariant BA.2. Among all the eligible respondents, 197 (8.71%) reported COVID-19 reinfection appearing during November – December, 2022 – an epidemic period with Omicron subvariant BA.5.2 being the most prevalent strain in local region and there was no reinfection case being reported before the period, and the self-reported median interval from previous infection to the reinfection was 98 (25th percentile: 93, 75th percentile: 104) days. For the 197 reinfections, 193 (97.97%) reported clinic symptoms including fever, throat ache and headache; 113 (57.36%) reported only having self-medication; more reinfections were reported by the respondents without COVID-19 vaccination compared to the respondents with 3 or 2 doses of COVID-19 vaccine.   Conclusion  The survey results suggest that Omicron variant-related SARS-CoV-2 reinfection is relatively low but the most of the reinfections are symptomatic. More researches and control measures on are needed for the control of SARS-CoV-2 reinfection.
  • loading
  • [1]
    Yahav D, Yelin D, Eckerle I, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity[J]. Clinical Microbiology and Infection, 2021, 27(3): 315 – 318. doi: 10.1016/j.cmi.2020.11.028
    [2]
    Sotoodeh Ghorbani S, Taherpour N, Bayat S, et al. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: a systematic review and meta-analysis[J]. Journal of Medical Virology, 2022, 94(1): 44 – 53. doi: 10.1002/jmv.27281
    [3]
    To KKW, Hung IFN, Ip JD, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing[J]. Clinical Infectious Diseases, 2021, 73(9): e2946 – e2951. doi: 10.1093/cid/ciaa1275
    [4]
    CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) variant – United State, December 1 – 8, 2021[J]. Morbidity and Mortality Weekly Report, 2021, 70(50): 1731 – 1734. doi: 10.15585/mmwr.mm7050e1
    [5]
    Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives[J]. Signal Transduction and Targeted Therapy, 2022, 7(1): 141. doi: 10.1038/s41392-022-00997-x
    [6]
    El-Shabasy RM, Nayel MA, Taher MM, et al. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic[J]. International Journal of Biological Macro-molecules, 2022, 204: 161 – 168. doi: 10.1016/j.ijbiomac.2022.01.118
    [7]
    Statistics OFN. Coronavirus (COVID-19) Infection Survey, charac-teristics of people testing positive for COVID-19, UK. 2022[EB/OL]. [2022 – 12 – 23].https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsinthecommunityinengland.
    [8]
    Bastard J, Taisne B, Figoni J, et al. Impact of the omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022[J]. EuroSurveillance, 2022, 27(13): 2200247.
    [9]
    Gautret P, Houhamdi L, Nguyen NN, et al. Does SARS-CoV-2 re-infection depend on virus variant?[J]. Clinical Microbiology and Infection, 2021, 27(9): 1374 – 1375. doi: 10.1016/j.cmi.2021.06.029
    [10]
    Nguyen NN, Houhamdi L, Hoang VT, et al. SARS-CoV-2 reinfection and COVID-19 severity[J]. Emerging Microbes and Infections, 2022, 11(1): 894 – 901. doi: 10.1080/22221751.2022.2052358
    [11]
    Ramos W, Guerrero N, Napanga-Saldaña EO, et al. Hospitaliza-tion, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: a national retrospective cohort study[J]. Human Resources for Health, 2022, 20(1): 86. doi: 10.1186/s12960-022-00787-0
    [12]
    李志丽, 李昱, 陈秋兰, 等. 复检核酸阳性的新型冠状病毒感染者分布及传染性特征分析[J]. 中华流行病学杂志, 2021, 42(10): 1750 – 1756.
    [13]
    谭小华, 康敏, 邓爱萍, 等. 广东省新型冠状病毒肺炎确诊病例出院后复检病毒核酸阳性特征及影响因素分析[J]. 中华预防医学杂志, 2022, 56(1): 49 – 55.
    [14]
    胡敏, 岳勇, 冯静, 等. 成都市复检核酸阳性新冠肺炎患者流行特征分析[J]. 中国公共卫生, 2022, 38(6): 758 – 761. doi: 10.11847/zgggws1137219
    [15]
    Cui Z, Liu P, Wang N, et al. Structural and functional characteriza-tions of infectivity and immune evasion of SARS-CoV-2 Omicron[J]. Cell, 2022, 185(5): 860 – 871.e13. doi: 10.1016/j.cell.2022.01.019
    [16]
    Xu K, Gao P, Liu S, et al. Protective prototype-beta and delta-omicron chimeric RBD-dimer vaccines against SARS-CoV-2[J]. Cell, 2022, 185(13): 2265 – 2278.e14. doi: 10.1016/j.cell.2022.04.029
    [17]
    Akinbami LJ, Biggerstaff BJ, Chan PA, et al. Reinfection with severe acute respiratory syndrome coronavirus 2 among previously infected healthcare personnel and first responders[J]. Clinical Infectious Diseases, 2022, 75(1): e201 – e207. doi: 10.1093/cid/ciab952
    [18]
    国务院应对新型冠状病毒肺炎疫情联防联控机制综合组. 新型冠状病毒肺炎防控方案(第九版)[J]. 中国病毒病杂志, 2022, 12(5): 331 – 338. doi: 10.16505/j.2095-0136.2022.0049
    [19]
    国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国病毒病杂志, 2022, 12(3): 161 – 169. doi: 10.16505/j.2095-0136.2022.0023
    [20]
    Fülöp GÁ, Lakatos B, Ruppert M, et al. A case series of SARS-CoV-2 reinfection in elite athletes[J]. International Journal of Environmental Research and Public Health, 2022, 19(21): 13798. doi: 10.3390/ijerph192113798
    [21]
    Flacco ME, Acuti Martellucci C, Baccolini V, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis[J]. European Journal of Clinical Investigation, 2022, 52(10): e13845.
    [22]
    Flacco ME, Acuti Martellucci C, Baccolini V, et al. COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospita-lization: meta-analysis[J]. Frontiers in Medicine, 2022, 9: 1023507. doi: 10.3389/fmed.2022.1023507
    [23]
    Al-Otaiby M, Krissaane I, Al Seraihi A, et al. SARS-CoV-2 rein-fection rate and outcomes in Saudi Arabia: a national retrospective study[J]. International Journal of Infectious Diseases, 2022, 122: 758 – 766.
    [24]
    Cohen C, Kleynhans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020 – 21[J]. The Lancet Infectious Diseases, 2022, 22(6): 821 – 834. doi: 10.1016/S1473-3099(22)00069-X
    [25]
    Borras-Bermejo B, Piñana M, Andrés C, et al. Characteristics of 24 SARS-CoV-2-sequenced reinfection cases in a tertiary hospital in Spain[J]. Frontiers in Microbiology, 2022, 13: 876409. doi: 10.3389/fmicb.2022.876409
    [26]
    中华人民共和国中央人民政府. 国务院联防联控机制公布《关于进一步优化落实新冠肺炎疫情防控措施的通知》[EB/OL]. 2022. [2022 – 12 – 25]. http://www.gov.cn/xinwen/2022-12/07/content_5730475.htm.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Article views (720) PDF downloads(154) Cited by()
    Proportional views
    Publishing history
    • Receive:  2023-01-16
    • Online:  2023-02-03
    • Published:  2023-04-10

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return